Ultimately, to ascertain the augmented tumor cytotoxicity of CD8+ T cells induced by the combined therapeutic approach, an ex vivo T‐cell‐mediated tumor cell lysis assay was conducted (Figure 2L). The gene discussed is CD8A; the disease is neoplasm.